The greater CAA severity in PSEN1 mutation-associated AD has been previously documented10 and is of particular relevance because of the greater risk with CAA for amyloid-related imaging abnormalities, vasogenic edema, and hemorrhage, which are limiting factors for anti-amyloid monoclonal antibody therapy. The gene discussed is PSEN1; the disease is Alzheimer disease.